Payment overview · 2025
General Payments
$684.13
25 reported records · 12 companies
Healthcare provider profile · identity verified
Paryus Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Critical Care Medicine · INGLEWOOD, CA · NPI 1619064912
Verified facts
What the public records show
CMS Open Payments records show Paryus Patel, MD received $684.13 in general payments during 2025 across 25 reported records.
GlaxoSmithKline, LLC. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.44 | 18.3% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$107.04 | 15.7% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $100.73 | 14.7% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $98.82 | 14.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.33 | 9.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.04 | 5.0% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $33.28 | 4.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.10 | 4.5% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.44 | 3.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $23.84 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.25 | 2.8% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $18.82 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $684.13 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $125.44 | 4 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $107.04 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $100.73 | 8 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $98.82 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.33 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $34.04 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $33.28 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 40 |
| Gabapentin | Gabapentin | 138 | 30 |
| Furosemide | Furosemide | 115 | 33 |
| Prednisone | Prednisone | 114 | 53 |
| Famotidine | Famotidine | 113 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 15 |
| Metformin Hcl | Metformin Hcl | 78 | 12 |
| Losartan Potassium | Losartan Potassium | 77 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 73 | 14 |
| Lisinopril | Lisinopril | 71 | suppressed |
| Omeprazole | Omeprazole | 70 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 14 |
| Trazodone Hcl | Trazodone Hcl | 61 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 12 |
| Sucralfate | Sucralfate | 58 | 16 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Meloxicam | Meloxicam | 53 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 11 |
| Carvedilol | Carvedilol | 52 | 11 |
| Montelukast Sodium | Montelukast Sodium | 52 | 15 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 48 | suppressed |
| Eliquis | Apixaban | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 27 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Baclofen | Baclofen | 39 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | 12 |
| Temazepam | Temazepam | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 13 |
| Azithromycin | Azithromycin | 32 | 28 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 14 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Desloratadine | Desloratadine | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Ambrisentan | Ambrisentan | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Micardis | Telmisartan | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Pirfenidone | Pirfenidone | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $684.13 · 25 records | GlaxoSmithKline, LLC. | Arikayce, DUPIXENT, LifeVest, NUPLAZID, OFEV, PAXLOVID, PULSESELECT, PURIFIED CORTROPHIN GEL, Physio-Stim, SMARTVEST, TRELEGY ELLIPTA, WINREVAIR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error